Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 690

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 690
---
 compliance with insider trading laws, rules and regulations, and any listing
standards applicable to the Company.

21

Section 16(a) Beneficial Ownership Reporting
Compliance

Section 16(a) of the Exchange
Act requires our executive officers, directors and persons who beneficially own more than 10% of a registered class of our equity securities
to file with the SEC initial reports of ownership and reports of changes in ownership of our shares of common stock and other equity securities.
These executive officers, directors, and greater than 10% beneficial owners are required by SEC regulation to furnish us with copies of
all Section 16(a) forms filed by such reporting persons.

Based solely on our review of
such forms furnished to us and written representations from certain reporting persons, we believe that all filing requirements applicable
to our executive officers, directors and greater than 10% beneficial owners were filed in a timely manner.

ITEM 11. EXECUTIVE COMPENSATION.

No compensation will be paid to our initial shareholders,
officers and directors, or any of their respective affiliates, prior to or in connection with the consummation of our initial business
combination. We pay Drugs Made In America Acquisition LLC a total of $10,000 per month for office space, administrative and support services.
Upon completion of our initial business combination or our liquidation, we will cease making these payments. Our sponsor, its service
providers, officers and directors, or any of their respective affiliates, will be reimbursed for any out-of-pocket expenses incurred or
such agreed-upon compensation as contracted in connection with activities on our behalf such as identifying potential target businesses
and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that
were made to our sponsor, officers, directors or our or their affiliates.

After the completion of our initial business combination,
members of our management team who remain with us, may be paid consulting, management or other fees from the combined company with any
and all amounts being fully disclosed to shareholders, to the extent then known, in the tender offer materials or proxy solicitation materials
furnished to our shareholders in connection with a proposed business combination. It is unlikely the amount of such compensation will
be known at the time, as it will be up to the directors of the post-combination business to determine executive and director compensation.
Any compensation to be paid to our officers will be determined, or recommenced, to the board of directors for determination, either by
a committee